Ailux announced the hiring of Lloyd Miller as the organization's new chief medical officer. Miller arrives directly from Johnson & Johnson, where he served as senior vice president and global head of translational science and medicine for immunology. The executive change was reported as part of a regular tracker monitoring ongoing promotions, departures, and strategic hires across the healthcare industry.
Key points
Lloyd Miller transitions from Johnson & Johnson to take the chief medical officer post at…: Lloyd Miller transitions from Johnson & Johnson to take the chief medical officer post at Ailux.
The new executive brings extensive leadership background in global translational science…: The new executive brings extensive leadership background in global translational science and immunology.
The leadership transition represents a notable addition to the recurring industry executi…: The leadership transition represents a notable addition to the recurring industry executive tracking series.
Sources checked by our analysis pipeline: 1
Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us, and we’ll share it with others. That’s right. Send us your changes, and we’ll find a home for them. Don’t be shy. Everyone wants to know who is coming and going.
And here is our regular feature in which we highlight a different person each week. This time around, we note that Ailux hired Lloyd Miller as chief medical officer. Previously, he worked at Johnson & Johnson, where he was senior vice president and global head, translational science & medicine for immunology.
But all work and no play can make for a dull chief medical officer.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
The nation's largest health insurer is initiating formal legal action over recent administrative evaluations regarding plan quality. This direct dispute centers on downgraded evaluations that assess performance across the company's designated federal health coverage programs. While court documents target the validity of these lower tier scores, the comprehensive arguments supporting the filing remain undisclosed.
Leadership at the engineering firm is currently evaluating a dual-track strategy to determine the future of its specialized automation business. Seeking a definitive exit or standalone structure, decision-makers are weighing public equity markets against a direct corporate divestment. This dual-track approach ensures the business unit has a clear path forward regardless of how external negotiations conclude.
The divestment allows Intuit to offload a major asset at a steep discount from its original valuation while navigating market pressures driven by artificial intelligence disruptions. Selling the platform generates capital for share buybacks and targeted AI research. Meanwhile, the transaction solidifies the acquiring firm's strategy of rolling established internet software brands into a unified operating framework.